Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
23-valent pneumococcal polysaccharide vaccine (CNBG)
- Development stage
- Unknown
- Lead developer
- China National Biotec
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The 23-valent pneumococcal polysaccharide vaccine (PPV23) developed by China National Biotec Group (CNBG), a subsidiary of Sinopharm, is a biologic indicated for the prevention of pneumococcal infections. It contains purified capsular polysaccharide antigens from 23 serotypes of *Streptococcus pneumoniae* (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F). The vaccine works by stimulating the immune system to produce serotype-specific antibodies, providing active immunization against invasive pneumococcal disease (IPD) and pneumonia. It is typically administered as a single 0.5 mL intramuscular injection and is indicated for adults and children aged 2 years and older. Clinical development has included Phase 4 trials (such as NCT04700618) to evaluate the safety and immunogenicity of revaccination in elderly populations.
- Other names
- PPV23PPV-23PPV 2323-valent pneumococcal polysaccharide vaccinePneumococcal vaccine polyvalent
02
Targets
CPS (Streptococcus pneumoniae capsular polysaccharide)
Beyond the preview
Go deeper on 23-valent pneumococcal polysaccharide vaccine (CNBG).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 23-valent pneumococcal polysaccharide vaccine (CNBG).